BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 194 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,310 | -37.8% | 750,053 | -38.1% | 0.05% | -26.1% |
| Q2 2023 | $8,536 | -16.2% | 1,212,547 | -0.7% | 0.07% | -17.9% |
| Q1 2023 | $10,189 | +3959.4% | 1,221,681 | +5493.3% | 0.08% | +2000.0% |
| Q4 2022 | $251 | -100.0% | 21,842 | -96.9% | 0.00% | -96.6% |
| Q3 2022 | $8,937,000 | +19.2% | 709,285 | +0.1% | 0.12% | +27.2% |
| Q2 2022 | $7,500,000 | +348.3% | 708,919 | +486.7% | 0.09% | +441.2% |
| Q4 2021 | $1,673,000 | +175.2% | 120,827 | +185.7% | 0.02% | +112.5% |
| Q3 2021 | $608,000 | -68.4% | 42,295 | -65.2% | 0.01% | -61.9% |
| Q2 2021 | $1,923,000 | +1024.6% | 121,603 | +238.1% | 0.02% | +425.0% |
| Q2 2020 | $171,000 | – | 35,969 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |